Mel-18 mRNA在胃癌中的表达及其临床意义

摘要

背景与目的:Mel-18为哺乳动物多梳基因家族(polycomb group)成员之一,许多实验研究证实其参与肿瘤的形成,为此我们检测胃痛组织中Mel-18的表达,以探讨其表达及其临床意义.方法:应用实时定量RT-PCR方法检测52例胃癌患者癌组织及其相应正常组织(距肿瘤10 cm以上)中Mel-18的表达,分析Mel-18表达水平改变与临床病理因素的相关性.结果:18例(34.62%)胃癌患者的肿瘤组织中Mel-18 mRNA 表达明显低于正常组织.Mel-18基因在不同年龄、性别、肿瘤大小和肿瘤分化程度间的表达差异均无显著性(P>0.05).Mel-18 mRNA的表达与患者的淋巴结转移和临床分期呈负相关(P<0.05).临床分期Ⅰ、Ⅱ、Ⅲ、Ⅳ期患者的Mel-18基因的表达分别为1.357、0.453、0.183和0.170,无淋巴结转移患者和有淋巴结转移患者分别为0.634和0.210,组间差异均有显著性(P<0.05).结论:Mel-18基因在胃癌的发生、发展中可能起重要作用,有可能成为预测胃癌预后的指标之一.%Background and purpose: Mel-18 is one of the mammalian polycomb group members. A number of related researches have implied that Mel-18 may play a role in human tumorigenesis.In this study, we measured the expression of Mel-18 in gastric carcinoma cells in vivo to explore the expression and clinical significance of Mel-18 in gastric carcinoma. Methods: Real time RT-PCR was used to detect the expression of Mel-18 in cancer tissue and corresponding normal tissue in 52 cases of gastric carcinoma. The association between Mel-18 expression and the clinicopathological parameters of the tumors was analyzed. Results: The analysis revealed that there was significantly decreased expression of Mel-18 in 18 (34.62%)carcinoma tissues in comparison with para-cancer normal tissue. There was no correlation between Mel-18 expression and clinicopathological parameters, such as age, gender, tumor size and histological differentiation (P>0.05).The decrease of Mel-18 expression was significantly negatively correlated with lymph node metastasis and clinical stage (P<0.05). The expression levels of Mel-18 evaluated by the ratios of gene expression were 1.357,0.453,0.183 and 0.170 in stage Ⅰ, Ⅱ,Ⅲ and Ⅳ gastric carcinoma, respectively. They were 0.634 and 0.210 in patients without lymph node metastasis and in patients with lymph node metastasis, respectively. Expression of Mel-18,lymph node metastasis, and clinical stage were significant covariates, respectively (P<0.05). Conclusion: Our results showed that Mel-18 might play a crucial role in tumorigenesis and progression of gastric carcinoma. It is possible that Mel-18 could be used as one of the biomarkers for predicting the prognosis of gastric carcinoma.